Cellino Biotech

Cellino Biotech is pioneering a closed-loop, autonomous manufacturing platform to scale personalized regenerative therapies. The company's proprietary technology stack combines AI, laser-based cell editing, and modular hardware (Nebula™) to overcome key bottlenecks in cell therapy: reproducibility, scalability, and the need for immunosuppression. By enabling distributed manufacturing of patient-specific iPSC-derived therapies, Cellino targets a broad pipeline of chronic degenerative conditions, positioning itself at the convergence of deep tech and biomedicine. The company is privately held and appears to be in a pre-clinical or platform development stage.

The Nebula™ platform: an autonomous, closed-loop biomanufacturing system integrating AI-driven image analysis (Deep Learning, Cellinoverse digital twin), laser-generated bubble technology for non-contact cell editing, and modular cassette-based hardware. Designed for scalable production of patient-specific (autologous) cell therapies from induced pluripotent stem cells (iPSCs).

Competes with other cell therapy manufacturing technology companies (e.g., Culture Biosciences, Senti Bio) and directly with biopharma firms developing allogeneic or autologous cell therapies for the same indications. Its unique differentiation is the integration of in-process, image-guided laser editing for cell selection and quality control within a fully closed-loop autonomous system.